Key result
The anti-CD18 antibody R15.7 administered before reperfusion significantly reduced infarct size (P=0.0002) and preserved left ventricular ejection fraction (43.6% vs 28.5%, P<0.01) in dogs.
Why the study?
Does an anti-CD18 antibody reduce infarct size and preserve left ventricular function in a canine model of ischemia and reperfusion?
RCT (n=24)
randomized
Does an anti-CD18 antibody reduce infarct size and preserve left ventricular function in a canine model of ischemia and reperfusion?
Absolute Event Rate: 19.5% vs 34.6%
p-value: p=0.0002
A single injection of an anti-CD18 antibody before reperfusion limits myocardial infarct size and preserves left ventricular function in a canine model of ischemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; leaves open translation of anti-CD18 cardioprotection to human ischemia-reperfusion injury.
Arai et al. (1996) conducted an RCT in Myocardial reperfusion injury (n=24). R15.7 (anti-CD18 antibody) vs. saline was evaluated on infarct size (p=0.0002). The anti-CD18 antibody R15.7 administered before reperfusion significantly reduced infarct size (P=0.0002) and preserved left ventricular ejection fraction (43.6% vs 28.5%, P<0.01) in dogs.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: